Improved histidinylated lPEI polyplexes for skeletal muscle cells transfection

Abstract : Linear Polyethylenimine (lPEI) is an efficient cationic polymer for transfecting cells, both in vitro and in vivo, but poses concerns regarding cytotoxicity. Histidinylated lPEI (His-lPEI) exhibits also high transfection efficiency but lower cytotoxicity than lPEI. For the first time, we tested polyfection efficiency of polyplexes comprising both lPEI and His-lPEI. A series of pDNA polyplexes was prepared with mixtures of lPEI and His-lPEI and the amount of each polymer within His-lPEI/lPEI polyplexes was determined by flow cytometry. We show that His-lPEI/lPEI polyplexes exhibit properties similar to lPEI polyplexes in terms of size, morphology, assembly with pDNA, and polyplex stability while His-lPEI/lPEI polyplexes exhibit properties similar to His-lPEI polyplexes in terms of buffering capacity. Compared to polyplexes consisting only of lPEI or His-lPEI, the transfection profile reveals that His-lPEI/lPEI polyplexes containing 30% to 57% lPEI strongly increase polyfection efficiency of NIH3T3 fibroblasts and murine, as well as human skeletal muscle cell lines without cytotoxicity. Importantly, improved transfection of human dystrophin deficient skeletal muscle cell lines was obtained. These results indicate that His-lPEI/lPEI polyplexes are an improved non-viral vector for efficient transfection of dystrophin deficient skeletal muscle cell lines that should be tested on animals.
Type de document :
Article dans une revue
International Journal of Pharmaceutics, Elsevier, 2019, 559, pp.58-67. 〈10.1016/j.ijpharm.2019.01.003〉
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-02067297
Contributeur : Isabelle Frapart <>
Soumis le : jeudi 14 mars 2019 - 10:47:52
Dernière modification le : samedi 16 mars 2019 - 01:18:48

Identifiants

Citation

Jean-Pierre Gomez, Guillaume Tresset, Chantal Pichon, Patrick Midoux. Improved histidinylated lPEI polyplexes for skeletal muscle cells transfection. International Journal of Pharmaceutics, Elsevier, 2019, 559, pp.58-67. 〈10.1016/j.ijpharm.2019.01.003〉. 〈hal-02067297〉

Partager

Métriques

Consultations de la notice

2